Ventricular Assist Devices: Challenges of the One-device Era
Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generati...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-11-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2022.01 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256421212389376 |
|---|---|
| author | Gassan Moady Shaul Atar Binyamin Ben-Avraham Tuvia Ben-Gal |
| author_facet | Gassan Moady Shaul Atar Binyamin Ben-Avraham Tuvia Ben-Gal |
| author_sort | Gassan Moady |
| collection | DOAJ |
| description | Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device – the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs. |
| format | Article |
| id | doaj-art-2b81f2b72d3f43ffbfc2d74af97f0b26 |
| institution | OA Journals |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-2b81f2b72d3f43ffbfc2d74af97f0b262025-08-20T01:56:39ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592022-11-01810.15420/cfr.2022.01Ventricular Assist Devices: Challenges of the One-device EraGassan Moady0Shaul Atar1Binyamin Ben-Avraham2Tuvia Ben-Gal3Department of Cardiology, Galilee Medical Center, Nahariya, Israel; Azrieli Faculty of Medicine, Bar Ilan University, Safed, IsraelDepartment of Cardiology, Galilee Medical Center, Nahariya, Israel; Azrieli Faculty of Medicine, Bar Ilan University, Safed, IsraelDepartment of Cardiology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Cardiology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelHeart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device – the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs.https://www.cfrjournal.com/articleindex/cfr.2022.01 |
| spellingShingle | Gassan Moady Shaul Atar Binyamin Ben-Avraham Tuvia Ben-Gal Ventricular Assist Devices: Challenges of the One-device Era Cardiac Failure Review |
| title | Ventricular Assist Devices: Challenges of the One-device Era |
| title_full | Ventricular Assist Devices: Challenges of the One-device Era |
| title_fullStr | Ventricular Assist Devices: Challenges of the One-device Era |
| title_full_unstemmed | Ventricular Assist Devices: Challenges of the One-device Era |
| title_short | Ventricular Assist Devices: Challenges of the One-device Era |
| title_sort | ventricular assist devices challenges of the one device era |
| url | https://www.cfrjournal.com/articleindex/cfr.2022.01 |
| work_keys_str_mv | AT gassanmoady ventricularassistdeviceschallengesoftheonedeviceera AT shaulatar ventricularassistdeviceschallengesoftheonedeviceera AT binyaminbenavraham ventricularassistdeviceschallengesoftheonedeviceera AT tuviabengal ventricularassistdeviceschallengesoftheonedeviceera |